Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients

J Thromb Thrombolysis. 2022 Jul;54(1):91-96. doi: 10.1007/s11239-021-02622-0. Epub 2022 Jan 24.

Abstract

This study was designed to explore the prevalence of recommended anticoagulation by guidelines before admission and its impact on the incidence of acute myocardial infarction (AMI) and the AMI associated in-hospital outcomes in patients with atrial fibrillation (AF). 10,725 patients with AF at their first hospitalizations in our hospitals were retrospectively reviewed, with a prevalence of recommended anticoagulation preadmission 24.41% (Number = 2618). They had lower risk of AMI incidence (Adjusted OR 0.66, 95%CI 0.54-0.81, p < 0.001) compared to those without recommended anticoagulation after multivariate logistic regression. Furthermore, recommended anticoagulation preadmission reduced in-hospital all-cause death associated with AMI in univariate logistic analysis, but had no impact on the risk of in-hospital bleeding and stroke after AMI both in univariate and multivariate logistic analysis. The prevalence of recommended anticoagulation before admission was 24.41% in China. Recommended anticoagulation reduced incidence of hospitalized AMI, but had no impact on the associated in-hospital bleeding and stroke risk after AMI.

Keywords: Acute myocardial infarction; All-cause death; Atrial fibrillation; Recommended coagulation.

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / epidemiology
  • Hemorrhage / chemically induced
  • Hospitals
  • Humans
  • Incidence
  • Myocardial Infarction* / complications
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • Stroke* / complications
  • Stroke* / epidemiology
  • Stroke* / prevention & control

Substances

  • Anticoagulants